RxDoctor Payments Data

Mark Oatman, MD

Family Medicine · Ponca City, OKNPI 1205814449

Payments from drug & device makers

$2,671in general payments, 2019–2025

Across 89 payments — averaging $30.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardinal Health 110 LLC$965
  • Collegium Pharmaceutical, Inc.$477
  • Forte Bio-pharma LLC$286
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$222
  • Si-bone, Inc.$145
  • GRT US Holding, Inc.$144
  • plus $432 from 13 others

What the payments were for

  • Consulting fees$96536%
  • Food & beverage$1,70664%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,671 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$57,134
Medicare patients
169
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArexvyRsvpref3 Antigen/As01e/Pf9,643$2,481,563
ShingrixVaricella-Zoster Ge/As01b/Pf12,975$2,351,983
AbrysvoRsv Vacc, Pref A And Pref B/Pf6,311$1,681,123
Boostrix TdapDiphth,pertuss(Acell),tet Vac4,128$240,426
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3,217$110,105
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,331$85,041
Xtampza ErOxycodone Myristate191$58,693
OxycontinOxycodone Hcl173$52,455
TwinrixHepatitis A And B Vaccine/Pf296$36,305
Oxycodone Hcl1,443$24,223
Fentanyl107$13,796
Hysingla ErHydrocodone Bitartrate33$12,748
Buprenorphine51$10,373
Morphine Sulfate ErMorphine Sulfate317$8,196
EliquisApixaban23$6,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$477$64,589202 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$222$5,36816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Ponca City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →